T cells

[eLife] The authors used induced PSC technology to investigate whether murine mucosal-associated invariant T (MAIT) cells functioned as tumor-promoting or inhibitory cells. MAIT cells were reprogrammed into iPSCs and redifferentiated towards MAIT-like cells.

[Haematologica] Scientists investigated the oncogenic function of TAL1 and the possible cooperation with PI3K-AKT pathway activation using isogenic pro-T cell cultures ex vivo and in vivo leukemia models.

[Nature Cancer] The authors presented the PROSECO prospective observational study on 457 patients with lymphoma that received two or three COVID-19 vaccine doses and showed undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment.

[Blood Advances] Scientists conducted a prospective single-center Phase II trial in which they added autologous anti-CD19 humanized binding domain T cells to ibrutinib in chronic lymphocytic leukemia patients not in complete remission despite at least six months of ibrutinib.

[Signal Transduction and Targeted Therapy] Via an unbiased genome-wide CRISPR/Cas9 screening, scientists identified loss of NOXA, a B-cell lymphoma 2 family protein in B cell malignancies, as a pivotal regulator of resistance to CAR T cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.

[Nature Biotechnology] By testing immunogenicity with autologous blood lymphocytes from patients with cancer, scientists detected pre-established CD4+ and CD8+ T cell responses for 10 of 21 and for 1 of 30 previously identified gene fusions, respectively.